Conference Details - Overview
Continuing Education Information
Physicians: Physicians' Education Resource is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.This activity is approved for AMA PRA Category 1 Credit™
Physician Assistants: AAPA accepts category 1 credit from AOACCME, Prescribed credit from AAFP, and AMA Category 1 CME credit for the PRA from organizations accredited by the ACCME.
The Next Generation of Monoclonal Antibodies in CLL and NHL
Hilton Americas-Houston
Houston, TX
September 25, 2008
Conference Overview
The care of hematologic malignancies, such as chronic lymphocytic leukemia and non-Hodgkin lymphoma, has been revolutionized by the integration of monoclonal antibodies into treatment. However, a substantial proportion of patients are refractory to these antibodies and others develop resistance, leading to the development of a number of second-generation treatments designed to overcome these limitations. The Next Generation of Monoclonal Antibodies in CLL and NHL symposium will educate physicians about novel monoclonal antibody therapies for chronic lymphocytic leukemia and non-Hodgkin lymphoma. Physicians who attend this program will be introduced to new clinical trial data on burgeoning therapeutics and will apply this information to appropriate patient scenarios.
This educational program is designed to be of high clinical utility to medical oncologists and hematologists with an interest in the treatment of chronic lymphocytic leukemia and non-Hodgkin lymphoma. Fellows, nurses, physician assistants, and pharmacists in oncology are also invited to attend.
At the conclusion of this symposium, you should be able to:- Describe the known mechanisms of resistance to anti-CD20 antibodies and the means by which therapeutic agents can overcome this resistance
- Discuss novel CD20-targeted monoclonal antibodies that have activity in chronic lymphocytic leukemia and follicular non-Hodgkin lymphoma
- Apply the current clinical trial data on monoclonal antibodies to patient scenarios representative of chronic lymphocytic leukemia and non-Hodgkin lymphoma
- Review current strategies for optimizing the use of CD20-targeted monoclonal antibodies in follicular non-Hodgkin lymphoma
Educational Grants
An educational grant for this activity was provided by:
- GlaxoSmithKline